CoGenesis™ 癌症基因測試

什麼是CoGenesis™ 癌症基因測試?

CoGenesis™ 癌症基因測試針對腫瘤組織進行準確的分子分析。通過使用新一代基因圖譜排序 (NGS),CoGenesis™ 癌症基因測試可檢測癌症基因的異常,這些癌症基因是誘發癌症的原因。因此, 我們積極開發藥物基因組學數據庫,讓CoGenesis™ 癌症基因測試分析為你尋找誘發癌症的變異基因,也協助醫生能夠為癌症患者提供精準個人化的臨床診治。

為什麼我們建議CoGenesis™ 癌症基因測試?

CoGenesis™ 癌症基因測試平台為癌症患者提供快速臨床診斷結果。

CoGenesis™ 癌症基因測試的好處

  • 提供定制的標靶治療和免疫治療建議
  • 減少潛在的副作用,縮短恢復時間
  • 確認腫瘤基因,以便更準確地進行臨床診斷

誰應該考慮CoGenesis™ 癌症基因測試?

  • 正在考慮標靶治療或免疫療法的患者
  • 對常規癌症療法效果不明顯的患者
  • 臨床醫生要求對腫瘤基因進行分析以便提供精準治療



  • CRC: pembrolizumab reported to have 72% 2-year overall survival in adults with treatment refractory metastatic mismatch repair-deficient colorectal cancer [1]
  • Lung cancer: first-line treatment with EGFR tyrosine kinase inhibitors is associated with improved progression free survival compared to platinum-based doublet chemotherapy in adults with EGFR mutation and stage IIIB-IV non-small cell lung cancer [2]. ROS1 gene must be performed in all lung adenocarcinoma. BRAF, RET, HER2, KRAS, MET should be tested if routine EGFR, ALK, and ROS1 testing are negative [3].
  • Breast cancer: Genetic testing should be made available to all newly diagnosed breast cancer patient. Testing should not be limited to BRCA1/2 [4]




CoGenesis™ Cancer 可以從我們合作夥伴的診所訂購。請聯繫我們獲取更多信息。


[1] Dung T.L.E. et. al, A pan-cancer biomarker is identified that can predict successful response to cancer immunotherapy in human patients. Science, 2017; 28 JUL 2017 pp 409-413

[2] Gao G. et al ., Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int. J. Cancer, 2012; 131: E822-E829

[3] Kalemkerian, G et. al., Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal Of Oncology Practice, 2018; 14(5), 323-327

[4] The American Society of Breast Surgeon, Consensus Guideline on Genetic Testing for Hereditary Breast Cancer, 2018